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Abstract
Mass testing for COVID-19 is essential to defining patient management strate-
gies, choosing the best clinical management, and dimensioning strategies for 
controlling viral dissemination and immunization strategies. Thus, it is of utmost 
importance to search for devices that allow a quick and reliable diagnosis of low 
cost that can be transposed from the bench to the bedside, such as biosensors. These 
devices can help choose the correct clinical management to minimize factors that 
lead to infected patients developing more severe diseases. The use of nanomateri-
als to modify biosensors’ surfaces to increase these devices’ sensitivity and their 
biofunctionality enables high-quality nanotechnological platforms. In addition to 
the diagnostic benefits, nanotechnological platforms that facilitate the monitoring 
of anti-SARS-CoV-2 antibodies may be the key to determining loss of protective 
immune response after an episode of COVID-19, which leads to a possible chance 
of reinfection, as well as how they can be used to assess and monitor the success of 
immunization strategies, which are beginning to be administered on a large scale 
and that the extent and duration of their protection will need to be determined. 
Therefore, in this chapter, we will cover nanomaterials’ use and their functionalities 
in the surface design of sensors, thus generating nanotechnological platforms in the 
various facets of the diagnosis of COVID-19.
Keywords: COVID-19, SARS-CoV-2, nanotechnological platforms, nanomaterials, 
biosensors, diagnosis, sensor surface design
1. Introduction
SARS-CoV-2 is a virus in the coronavirus family, discovered in December 2019 
in Wuhan, China, and the cause of COVID-19. [1] Coronaviruses (CoV) are RNA 
viruses and can cause anything from the common cold to more serious diseases 
with neurological, gastrointestinal, and pulmonary involvement.[2] They are 
zoonotic viruses; that is, they can be transmitted between animals and people due 
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to their ability to recombine their viral proteins between coronaviruses of different 
hosts.[3].
COVID-19 was defined as Pandemic on March 11, 2020 (1), and by February 1, 
2021, there are already 103,221,369 individuals infected worldwide, and the num-
ber of global deaths already exceeds 2,232,563.[4] Before SARS-CoV-2, two other 
CoVs causing a pandemic disease were identified: the first was SARS-CoV in 2002, 
originating in Foshan (China), which caused Severe Acute Respiratory Syndrome 
(SARS); the second was MERS-CoV, which originated in the Arabian Peninsula in 
2012, causing the Middle East Respiratory Syndrome (MERS).[5].
A significant bottleneck in COVID-19 is mass diagnosis. The real-time reverse-
transcription polymerase chain reaction (RT-PCR) is the “gold standard” method 
for demonstrating the presence of SARS-CoV-2. This diagnosis is reliable; however, 
most countries have suffered from a lack of supplies and equipment and its high 
cost. IgM and IgG antibodies can be detected in the serum of patients with COVID-
19, where their monitoring can indicate recent or late infection and the duration of 
the post-infection protective immune response.
The development of easy-to-use alternative platforms is encouraged with 
specific attention paid to sensitivity and simplicity to specifically detect targets at a 
very low concentration, in about minutes, enabling portable on-site screening upon 
further optimizations of the detection limit. However, the accuracy of these tech-
niques depends on several factors; variations in these factors might significantly 
lower the sensitivity of detection.
Nanomaterials can be applied in several types of sensors due to their physical 
and chemical properties, making them possible to detect by colorimetric, fluo-
rescence, magnetism, surface plasmon resonance, and electrochemical. [6–10] In 
electrochemical sensing, the conductive nanomaterials are interesting for applica-
tion due to their well-known ability to improve the catalytic activity, the electron 
transfer speed, and the conductivity of the sensors. Furthermore, the superficial 
area and amplify the analytical signal can be increased by deposition of nanomate-
rials over electronic surfaces, enhancing the sensitivity regarding target analytes’ 
detection. Therefore, the group has been working with several nanomaterials to 
develop sensors.
Therefore, in this book chapter, we describe case reports and proof-of-concept 
for a simple, label-free electrochemical sensor for the fast and direct detection of 
SARS-CoV-2 through the detection of the specific probe. Early and widespread 
testing has proven to reduce mortality rates and improve contact tracing. However, 
the value of testing is directly linked to the availability and accuracy of diagnostic 
tests as concerns grow. Additionally, we have demonstrated in this work the pos-
sibility of a biorecognition element between the target concentration and the viral 
load exploring different electrode materials and redox markers allows for improved 
sensor properties with higher effectiveness than the commercially available assay or 
traditional diagnostic methods.
2. Diagnosis of COVID-19: the old and the gold
Coronaviruses infect human cells mainly by binding proteins from viral spikes 
(spike proteins) to molecules of the angiotensin-converting enzyme 2 (ACE2), [11] 
widely expressed in human organs and tissues, such as nasal, bronchial epithelial 
cells, and pneumocytes. After entering the cell, viral replication occurs and the host 
cell’s subsequent death, whether epithelial, endothelial, or immune cells.[12].
Due to the increase in viral replication, the epithelial-endothelial barrier’s 
integrity is compromised, accentuating the inflammatory response, causing edema 
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and inflammatory infiltrates. Furthermore, it compromises coagulation pathways, 
increasing fibrin degradation products and alterations in leukocytes and red blood 
cells. Together with the inflammatory infiltrate, the resulting edema contributes to 
the ground-glass opacities seen in imaging studies and too low oxygenation.[13].
Symptoms and clinical evolution depend on the triad: virus strain, host immu-
nity, and pre-existing conditions, known as comorbidities, such as hypertension, 
obesity, diabetes, cardiovascular disease, chronic lung disease, chronic kidney 
disease, and malignancies. [14] Symptoms range from the most common in flu-like 
conditions, such as fever, cough, and shortness of breath, nausea, diarrhea, loss of 
smell and taste, and more severe symptoms such as pneumonia leukopenia, kidney 
failure, myocarditis, meningitis, and thromboembolic events. [15].
The immune response against COVID-19 has been extensively investigated and 
is directly related to clinical evolution. The presence of lymphopenia and increased 
production of chemokines and proinflammatory cytokines have been demonstrated 
in patients with COVID-19, especially in the most severe cases, which can worsen 
tissue damage.[16] Serum levels of chemokines (IL-8) and proinflammatory cyto-
kines (TNF-α, IL-1, IL-6, IFN-γ, IP-10, and MCP-1) are found in greater quantities 
patients with COVID- 19 severe when compared with individuals with mild disease. 
This fact indicates that the cytokine storm is associated with the severity of the 
disease and adverse outcomes, suggesting a possible role of hyperinflammatory 
responses in the pathogenesis of COVID-19.[16, 17].
Studies on the humoral immune response demonstrate that antibodies, such as 
IgA, IgM, and IgG against SARS-CoV-2, appear on the first day after the onset of 
symptoms.[18, 19] IgM levels appear on days 0 to 7, increasing on days 8 to 14 and 
reaching a plateau, while IgA levels increased from days 0 to 14, whereas IgG levels 
were detected on days 0 to 7, increased on days 8 to 14, continued to increase until 
the 15th to the 21st and reached a plateau on the 21st. [18] This kinetics of antibody 
levels indicates a rapid and almost simultaneous response of these three isotypes 
during the first weeks of infection by SARS-CoV-2, IgA and IgG remain with higher 
titers for a longer time when compared to IgM. [20, 21].
The amount of antibodies in samples from patients with COVID-19 is dependent 
on the number of viral RNA present: the lower the viral load, the lower the level 
of antibodies present, and the severity of clinical evolution.[19–21] Initial data 
indicate a lower concentration of anti-SARS-CoV-2 antibodies in asymptomatic 
patients, but more quickly, while in mild symptomatic ones, there is a slower but 
more continuous production. Serious patients have high levels of antibodies, mainly 
IgA and IgG. However, there are still gaps about whether specific humoral and 
cellular immune memory persist and for how long.[20] Despite these limitations 
in understanding the long-term humoral immune response, the determination of 
IgA, IgM, and IgG antibodies are widely used in laboratory tests for the detection 
of COVID-19. Early diagnosis also allows the infected patient to have faster access 
to medical care and increases their chances of a better prognosis. It will enable the 
initiation of treatment when the viral load is in low concentrations.
Antibody determination is also important to monitor patients who have been 
vaccinated since immunization stimulates the immune system’s production without 
having to be infected.[22] Results about vaccines against COVID-19 showed that 
vaccinated patients increased the production of specific antibodies and their affin-
ity to levels similar to those observed in patients who recovered from COVID-19.
[23–25] Data show that a standardized quantification/determination of antibody 
levels may be sufficient to monitor vaccinated patients and estimate the quality and 
duration of this protection.[24].
To date, quantitative real-time reverse-transcription polymerase chain reaction 
(RT-PCR), qRT-qPCR assay is the gold standard for the early detection of virus 
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(major steps presented in Figure 1), but the CRISPR–Cas12-based lateral flow, 
Immunochromatographic, ELISA, loop-mediated isothermal amplification (LAMP) 
and other techniques has been developed and applied to screening or to confirm 
positive COVID-19 patients allowing prompt clinical and quarantine decisions this 
infection (Table 1).
To minimize the cost and logistical problems of sample collection and diagnos-
tics, rapid diagnostic systems based on classical methodological approaches, such 
as immunochromatography, were quickly implemented in the detection of SARS-
CoV-2 antigens or antibodies produced against it. However, the accuracy of these 
techniques depends on several factors. The bioavailability of the researched mol-
ecule, as viral genetic material, viral antigens, and various subclasses of antibod-
ies, the stability of these biomolecules to the procedures of sample collection and 
transport to the diagnostic platforms, the possibility of storage for later evaluation 
are significant bottlenecks that have impaired mass testing, especially in developing 
countries and variations in these factors might significantly lower the sensitivity of 
detection. The degree of reliability is uncertain in many of them, and implementing 
a faster and accurate diagnosis system is essential to monitor the disease and define 
policies to control viral spread.
Biosensors are one of the most popular types of point-of-care devices in 
various diagnostics areas, which offer several advantages such as the low cost, the 
capability of miniaturization, and high sensitivity and selectivity. The transposi-
tion of the molecular and immunological diagnosis to miniaturization platforms 
like point-of-care systems implies a drastic reduction in the amount of sample 
needed, increases specificity, reliable measurements in real-time, and portabil-
ity. The development of easy-to-use alternative platforms is encouraged with 
specific attention paid to sensitivity and simplicity to detect targets at a very low 
concentration in about minutes, enabling portable on-site screening upon further 
optimizing the detection limit.
Figure 1. 
Major steps of qRT-PCR as a diagnostic tool at COVID-19 (1) A patient suspected of COVID-19 undergoes 
collection of cells infected with SARS-CoV-2 through a nasopharyngeal swab. (2–3) Viral RNA is extracted and 
purified. The enzyme reverse transcriptase converts RNA into cDNA.
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Table 1. 
Comparison of methodologies applied to the diagnosis of (SARS)-CoV-2.
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An overview of some methodologies applied to the diagnosis of (SARS)-CoV-2 
is presented in Table 1. The ELISA-based test was used to validate the antibody–
antigen interaction, or RT-PCR was used to validate the primer, particularly the 
complexity of the assays during inventory shortages, while cyclic voltammetry, 
electrochemical impedance spectroscopy, differential pulse voltammetry was used 
to characterize the electrode functionalization.
Multi sensors, lateral flow tests, mobile biosensors, and wearable biosensors 
are critical parts for precision medicine in COVID-19. Russell, S.M. et al., defined 
these biosensors’ ideal characteristics using some prototypes from recent literature 
as examples. [26] Multi sensors, lateral flow tests, mobile biosensors, and wearable 
biosensors are crucial parts for precision medicine in COVID-19. We propose the 
ideal characteristics of these biosensors using some prototypes from recent litera-
ture as examples. Multi sensors, lateral flow tests, mobile biosensors, and wearable 
biosensors are crucial parts for precision medicine in COVID-19.
In his work, Fukumoto, T. et al. 2020 has developed a fast, easy to use, and 
inexpensive diagnostic method that is needed to help control the current outbreak 
of the new coronavirus based on microfluidic microdevices. A new detection kit - 
the 2019 Novel Coronavirus Detection Kit (nCoV-DK) - cuts detection time in half, 
eliminating RNA extraction and purification steps. The nCoV-DK test effectively 
detects SARS-CoV-2 in all types of samples, including saliva, while reducing the 
time required for detection and risk of human error.[27].
Laghrib, F. et al., showed the leading current trends and strategies in diagnos-
ing n-SARS-CoV-2 based on emerging and traditional assessment technologies 
for continuous innovation. Addressing recent biosensors trends to build a fast, 
reliable, more sensitive, accessible, friendly system with easily adaptable n-SARS-
CoV-2 detection and monitoring technology.[28] Overall, we address and identify 
evidence from research that supports biosensors’ use based on the premise that 
screening people for n-SARS-CoV-2 is the best way to stem its spread. The detec-
tion and notification of infectious pathogens in a fast, sensitive, and specific way is 
essential for managing the patient and surveillance of outbreaks. With their ability 
to diagnose in real-time with the high specificity of a low concentration sample, 
biosensors are much more reliable than the rapid test for coronavirus detection. 
The use of nano biosensors has been considered the most promising approach for 
detecting new n-SARSCoV-2 coronavirus disease. Meanwhile, the current work has 
also tried to improve biosensors’ detection sensitivity, simplicity, and performance.
Hui, X. et al. 2020, showed in his work, G quadruplex-based Biosensor: A poten-
tial tool for SARS-CoV-2 detection to discover additional advantageous attributes 
of G-quadruplex as potential to be used in new biosensors, such as ligand binding 
enhanced and unique folding properties.[29] The newly developed G-quadruplex 
biosensors include electrochemical and optical biosensors that have shown better 
performance with potential applications with a wide detection range and a broad 
spectrum of pathogens SARS-CoV-2, the causative agent of COVID-19 disease. 
G-quadruplex is a non-canonical nucleic acid structure formed by the folding of 
guanine-rich DNA or RNA.
3.  Platform with nanomaterials in the diagnosis of COVID-19: a brave 
new world
Biosensors are analytical devices that incorporate a biological recognition 
element capable of detecting the presence, activity, or concentration of the sample 
under analysis connected to a transducer. This biological element can be a micro-
organism, an antibody, oligonucleotides, lectins, biomolecule enzymes that can 
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interact with the target substrate. About the transducer, it can be an electrode, fiber 
optic, or oscillating quartz. [28, 44] Thus, biosensors are one of the most popular 
types of point-of-care devices in various areas of diagnostics, which offer several 
advantages such as low cost, the capability of miniaturization, and high sensitivity 
and selectivity.
Immunosensors are analytical devices of the biosensor class, which detect 
and transmit information regarding biochemical changes involving integrating a 
biological element with an electronic interface.[45, 46] This integration can convert 
a biological signal into an electrical response that is proportional to the concentra-
tion of the analyte. Thus, these biosensors can recognize a specific antibody or 
antigen by forming an antigen–antibody immunocomplex. The recognition event 
is detected and converted, through a transducer, to a measurable signal (such as 
electrical current, for example). The primary transducers used in immunosensors 
are electrochemical, optical, and piezoelectric. Therefore, the incorporation of 
specific nanomaterial can be intensified by improving the biosensor’s sensitivity 
and versatility.
Genosensors can also be used, a specific type of biosensor based on nucleic 
acid chemistry phenomena, such as the hybridization process. [47] Nucleic acids 
have been widely used in the development of biosensors for drug detection, iden-
tification of pathogenic microorganisms and other biological substances, and the 
diagnosis of diseases. The sensory technique through hybridization involves the 
immobilization of an oligonucleotide probe on the surface of a transducer and sub-
sequent sensor exposure to a sample containing the complementary sequence (tar-
get oligonucleotide) with consequent hybridization. Complementary DNA (cDNA) 
is a DNA synthesized from a messenger RNA molecule in a reaction catalyzed by 
the enzyme reverse transcriptase. Thus, the incorporation of nanomaterials on the 
biosensor’s surface ensures the enhancement of the electrochemical response.
Our group has been demonstrating through publications and patents expertise 
in the development of nanomaterials with specific properties, such as increased 
sensitivity of some devices, biocompatibility, and low genotoxicity, essential 
properties in developing nanotechnological platforms. [48–53] Toxicity is an impor-
tant parameter in nanomaterials, but depending on synthesis methodologies it is 
possible to decrease toxicity. For example, Silva et al. demonstrated some toxicities 
of nanomaterials, some influenced by the crystalline phase, composition or type 
of material. [54–61] In relation to quantum dots, synthesis methodologies were 
developed, making it possible to increase cellular viability and specificity aiming at 
several applicability as biological probes. [52, 53, 62–68].
The development of artificial intelligence software enables more accurate detec-
tion and quantification and low-cost analytical platforms. [69, 70] These nanotech-
nological platform [71] s can be used in large-scale production, with low cost and 
low consumption of samples and reagents.[6, 72].
High-quality, low-cost nanotechnological platforms based on the detection of 
anti-SARS-CoV-2 antibodies may be the key to defining groups already exposed 
to the disease, even if asymptomatic, that have a potentially protective immune 
response, a crucial factor for delimitation priority immunization groups. Besides, 
we can determine the loss of protective immune response after an episode of 
COVID-19, which leads to a possible chance of reinfection. Some advantages are the 
amount of sample of interest, in the order of μL, simultaneous analysis of several 
analytes in the same device and miniaturization, being portable, light, and easy 
to use the equipment. Also, nanotechnological platforms can be used to assess and 
monitor the success of immunization strategies, which should soon begin to be 
administered on a large scale, and the extent and duration of their protection will 
need to be determined.
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Several diagnostic methods have been reported, aiming at biomedical applica-
tions, especially in the diagnosis of covid-19, to detect the coronavirus in clinical, 
research, and public health laboratories. Based on biosensors for SARS-CoV-2, diag-
nostic methods presented have analytical performance and response times ranging 
from a few minutes to several hours, which make them promise for practical use in 
health care points, showing as a strong ally for control of endemics and pandemics.
An overview of current efforts to improve point-of-care diagnostic systems 
based on biosensors using different nanomaterials at COVID-19 is presented in 
Table 2.
Currently, diverse electrochemical biosensors have been lately developed for the 
detection of the SARS-CoV-2 using modified electrodes with metallic nanoparticle 
or nano-islands or nanostars, carbon nanofiber (CNF), using inorganic quantum 
dots, zinc oxide nanowires (ZnO NWs) or nanorods, bimetallic nanoparticles, 
Graphene Oxide (GO) nanosheet and other modifications show in Table 2. These 
nanomaterials showed excellent applications in biosensors because of their ease 
of functionalization, large surface area, stability, on the stable immobilization of 
probe molecules, the blocking reagent to minimize nonspecific binding, high elec-
tronic conductivity (accelerate the electron transfer), high carrier/charge mobility, 
and strong adsorption capability that increase the sensitivity of electrochemical 
platform due to their excellent unmatched properties followed by enhancement in 
the electrochemical response toward the selective detection of SARS-CoV-2.
Vadlamani, B S. et al., the synthesis of a TiO2 functionalized with cobalt but sus-
ceptible electrochemical sensor based on nanotubes (Co-TNTs) for rapid detection 
of SARS-CoV-2 using peak detection (binding domain receptor (RBD)) present on 
the virus surface. [73] A simple, low-cost, one-step electrochemical anodization 
route was used to synthesize TNTs, followed by an incipient wetting method for 
cobalt functionalization of the TNT platform, which was connected to a potentio-
stat for data collection. This sensor specifically detected the S-RBD protein from 
SARS-CoV-2, even at very low concentrations (range 14 to 1400 nM (nanomolar)). 
Besides, our sensor showed a linear response in the detection of viral protein in the 
concentration range. Thus, our Co-TNT sensor is highly effective in detecting the 
SARS-CoV-2 S-RBD protein in approximately 30s.
Cuy and Zhou, 2019, showed in their review work that timely detection and 
diagnosis are urgently needed to guide epidemiological measures, infection control, 
antiviral treatment, and vaccine research.[74] In this review, biomarkers/indicators 
for diagnosis of coronavirus 2019 disease or detection of severe acute respira-
tory syndrome coronavirus 2 in the environment are summarized and discussed. 
However, antibody detection methods can be combined with real-time quantitative 
polymerase reverse transcriptase chain reaction to improve diagnostic sensitivity 
and specificity and boost vaccine research significantly. The deep throat saliva and 
induced sputum are desired for the RT-qPCR test or other early detection technolo-
gies. The ultra-sensitive and specific laboratory diagnostic method and portable 
devices are essential to control the rapidly evolving COVID-19 pandemic associated 
with SARS-CoV-2. Currently, computed tomography, RT-qPCR, and LFICS based 
on the colloid Au NPs (colloidal gold method) have been developed.
Based on the table results, we can verify that the biosensors that showed the best 
sensitivities are using carbon-based materials due to their conductive properties, 
metallic oxides (ZnO and TiO2) with supercapacitor properties, and nanocompos-
ites (containing the capacitive and metallic systems).
In nanomaterials, the effects of size, morphology, and chemical structures have 
a strong influence on the optical, electrical, and magnetic properties. Thus, the 
tuning of these parameters allows maintaining the same material and intensifying 
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Table 2. 
Comparison of electrochemical biosensors for the detection of (SARS)-CoV-2.
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nanomaterials, several biosensors using more than one type of nanomaterials 
to further improve sensitivity. Thus, unfortunately, this systematic study of the 
literature in biosensors does not exist, being difficult to compare the sensitivity 
properties using different materials and nanocomposites.
4. Conclusion
Therefore, this chapter showed use of systems in diagnosis COVID-19 and how 
the nanomaterials may enable an improvement in sensitivity when being incorpo-
rated in the surface design of sensors, thus generating nanotechnological platforms. 
The functional improvement of biosensors using nanomaterials has undoubted 
benefits, both from the point of view of biological samples, ease of technical 
execution, better distribution and application logistics and better cost–benefit, 
being able to direct a whole new generation of rapid diagnoses easily transposable 
to combat other human diseases. These nanotechnological platforms could be 
the revolution for the mass diagnosis of COVID-19, without implying an increase 
in investments since it is a low-cost diagnostic proposal. In this way, they can be 
immediately translated into clinical practice and used in all parts of the health chain 
used to combat COVID-19, given its simplicity of use, biosafety, and low cost. The 
use of nanotechnology to modify diagnostic platforms has a special impact as they 
generate patents, strengthen technology, and arouse worldwide interest for their 
technological robustness, which may impact the attraction of resources to countries 
through the export of these or other forms of sharing that be advantageous.
Acknowledgements
This work was supported by grants of CNPq, CAPES, FAPEAL, and FAPEMIG.
Conflict of interest
The authors declare no conflict of interest.
13
Sensor Surface Design with NanoMaterials: A New Platform in the Diagnosis of COVID-19
DOI: http://dx.doi.org/10.5772/intechopen.97056
Author details
Eliete A. Alvin1,2,3, Anna V.B. e Borges4, Rhéltheer de P. Martins5,  
Marcela R. Lemes4, Rafaela M. Barbosa4, Carlo J.F. de Oliveira4, Diógenes Meneses3, 
Bruno G. Lucca6, Noelio O. Dantas1, Virmondes R. Junior4, Renata P.A. Balvedi5, 
Fabiane C. de Abreu3, Marcos V. da Silva4 and Anielle C.A. Silva1,2*
1 Laboratory of New Nanostructured and Functional Materials, Physics Institute, 
Federal University of Alagoas, Maceió, AL, Brazil
2 Programa de Pós-Graduação da Rede Nordeste de Biotecnologia (RENORBIO), 
Federal University of Alagoas, Maceió, AL, Brazil
3 LEMAN, Institute of Chemistry and Biotechnology, Federal University of 
Alagoas, Maceió, AL, Brazil
4 Department of Microbiology, Immunology and Parasitology, Institute of Bilogical 
and Natural Sciences, Federal University of Triângulo Mineiro, Uberaba, MG, 
Brazil
5 Federal University of Triângulo Mineiro, Iturama, MG, Brazil
6 Institute of Chemistry, Federal University of Mato Grosso do Sul, 
Campo Grande, MS, Brazil
*Address all correspondence to: acalmeida@fis.ufal.br
© 2021 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
14
Biotechnology to Combat COVID-19
[1] Organization, W.H. Novel 
Coronavirus (2019-nCoV) Situation 
Report – 1 2020.
[2] Benvenuto, D.; Giovanetti, M.; 
Ciccozzi, A.; Spoto, S.; Angeletti, S.; 
Ciccozzi, M. The 2019-new coronavirus 
epidemic: Evidence for virus evolution. 
J. Med. Virol. 2020, 92, 455-459, 
doi:10.1002/jmv.25688.
[3] Ji, W.; Wang, W.; Zhao, X.; Zai, J.; 
Li, X. Cross-species transmission of the 
newly identified coronavirus 2019-
nCoV. J. Med. Virol. 2020, 92, 433-440, 
doi:10.1002/jmv.25682.
[4] Hopkings, J. COVID-19 dashboard 
by the Center for Systems Science and 
Engineering (CSSE) at Johns Hopkins 
University (JHU) 2020.
[5] Cui, J.; Li, F.; Shi, Z.L. Origin and 
evolution of pathogenic coronaviruses. 
Nat. Rev. Microbiol. 2019, 17, 181-192.
[6] de França, C.C.L.; Meneses, D.; Silva, 
A.C.A.; Dantas, N.O.; de Abreu, F.C.; 
Petroni, J.M.; Lucca, B.G. Development 
of novel paper-based electrochemical 
device modified with CdSe/CdS magic-
sized quantum dots and application for 
the sensing of dopamine. Electrochim. 
Acta 2021, 367, doi:10.1016/j.
electacta.2020.137486.
[7] da Silva, M.P.G.; Candido, A.C.L.; 
de Araújo-Júnior, J.X.; Silva, A.C.A.; 
Dantas, N.O.; de Aquino, T.M.; de 
Abreu, F.C. Evaluation of the interaction 
of a guanylhydrazone derivative 
with cobalt ferrite nanoparticles and 
PAMAM electrochemical and UV/
visible spectroscopic techniques. J. Solid 
State Electrochem. 2020, 25, 743-752, 
doi:10.1007/s10008-020-04848-z.
[8] de Lima França, C.C.; da Silva 
Terto, E.G.; Dias-Vermelho, M. V.; 
Silva, A.C.A.; Dantas, N.O.; de Abreu, 
F.C. The electrochemical behavior 
of core-shell CdSe/CdS magic-sized 
quantum dots linked to cyclodextrin for 
studies of the encapsulation of bioactive 
compounds. J. Solid State Electrochem. 
2016, 20, 2533-2540, doi:10.1007/
s10008-016-3221-8.
[9] Martins, B.R.; Barbosa, Y.O.; 
Andrade, C.M.R.; Pereira, L.Q.; 
Simão, G.F.; de Oliveira, C.J.; Correia, 
D.; Oliveira, R.T.S.; da Silva, M. V.; 
Silva, A.C.A.; et al. Development of 
an Electrochemical Immunosensor 
for Specific Detection of Visceral 
Leishmaniasis Using Gold-Modified 
Screen-Printed Carbon Electrodes. 
Biosensors 2020, 10, 81, doi:10.3390/
bios10080081.
[10] Petroni, J.M.; Lucca, B.G.; 
da Silva Júnior, L.C.; Barbosa Alves, 
D.C.; Souza Ferreira, V. Paper-based 
Electrochemical Devices Coupled to 
External Graphene-Cu Nanoparticles 
Modified Solid Electrode through 
Meniscus Configuration and their Use 
in Biological Analysis. Electroanalysis 
2017, 29, 2628-2637, doi:10.1002/
elan.201700398.
[11] Hoffmann, M.; Kleine-Weber, H.; 
Schroeder, S.; Krüger, N.; Herrler, T.; 
Erichsen, S.; Schiergens, T.S.; Herrler, 
G.; Wu, N.H.; Nitsche, A.; et al. SARS-
CoV-2 Cell Entry Depends on ACE2 
and TMPRSS2 and Is Blocked by a 
Clinically Proven Protease Inhibitor. 
Cell 2020, 181, 271-280.e8, doi:10.1016/j.
cell.2020.02.052.
[12] Sungnak, W.; Huang, N.; Bécavin, 
C.; Berg, M.; Queen, R.; Litvinukova, 
M.; Talavera-López, C.; Maatz, H.; 
Reichart, D.; Sampaziotis, F.; et 
al. SARS-CoV-2 entry factors are 
highly expressed in nasal epithelial 
cells together with innate immune 




Sensor Surface Design with NanoMaterials: A New Platform in the Diagnosis of COVID-19
DOI: http://dx.doi.org/10.5772/intechopen.97056
[13] Xu, Z.; Shi, L.; Wang, Y.; Zhang, 
J.; Huang, L.; Zhang, C.; Liu, S.; Zhao, 
P.; Liu, H.; Zhu, L.; et al. Pathological 
findings of COVID-19 associated with 
acute respiratory distress syndrome. 
Lancet Respir. Med. 2020, 8, 420-422, 
doi:10.1016/S2213-2600(20)30076-X.
[14] Yang, J.; Zheng, Y.; Gou, X.; Pu, 
K.; Chen, Z.; Guo, Q.; Ji, R.; Wang, 
H.; Wang, Y.; Zhou, Y. Prevalence 
of comorbidities and its effects in 
coronavirus disease 2019 patients: A 
systematic review and meta-analysis. 
Int. J. Infect. Dis. 2020, 94, 91-95, 
doi:10.1016/j.ijid.2020.03.017.
[15] Esakandari, H.; Nabi-Afjadi, M.; 
Fakkari-Afjadi, J.; Farahmandian, 
N.; Miresmaeili, S.M.; Bahreini, E. A 
comprehensive review of COVID-19 
characteristics. Biol. Proced. Online 
2020, 22, 19.
[16] Qin, C.; Zhou, L.; Hu, Z.; Zhang, S.; 
Yang, S.; Tao, Y.; Xie, C.; Ma, K.; Shang, 
K.; Wang, W.; et al. Dysregulation 
of immune response in patients with 
coronavirus 2019 (COVID-19) in 
Wuhan, China. Clin. Infect. Dis. 2020, 
71, 762-768, doi:10.1093/cid/ciaa248.
[17] Huang, C.; Wang, Y.; Li, X.; Ren, 
L.; Zhao, J.; Hu, Y.; Zhang, L.; Fan, G.; 
Xu, J.; Gu, X.; et al. Clinical features 
of patients infected with 2019 novel 
coronavirus in Wuhan, China. Lancet 
2020, 395, 497-506, doi:10.1016/
S0140-6736(20)30183-5.
[18] Guo, L.; Ren, L.; Yang, S.; Xiao, 
M.; Chang, D.; Yang, F.; Dela Cruz, 
C.S.; Wang, Y.; Wu, C.; Xiao, Y.; et al. 
Profiling early humoral response to 
diagnose novel coronavirus disease 
(COVID-19). Clin. Infect. Dis. 2020, 71, 
778-785, doi:10.1093/cid/ciaa310.
[19] Wang, Y.; Zhang, L.; Sang, L.; 
Ye, F.; Ruan, S.; Zhong, B.; Song, T.; 
Alshukairi, A.N.; Chen, R.; Zhang, Z.; 
et al. Kinetics of viral load and antibody 
response in relation to COVID-19 
severity. J. Clin. Invest. 2020, 130, 5235-
5244, doi:10.1172/JCI138759.
[20] Carsetti, R.; Zaffina, S.; Mortari, 
E.P.; Terreri, S.; Corrente, F.; 
Capponi, C.; Palomba, P.; Mirabella, 
M.; Cascioli, S.; Palange, P.; et al. 
Different Innate and Adaptive Immune 
Responses to SARS-CoV-2 Infection 
of Asymptomatic, Mild, and Severe 
Cases. Front. Immunol. 2020, 11, 3365, 
doi:10.3389/fimmu.2020.610300.
[21] Figueiredo-Campos, P.; 
Blankenhaus, B.; Mota, C.; Gomes, 
A.; Serrano, M.; Ariotti, S.; Costa, C.; 
Nunes-Cabaço, H.; Mendes, A.M.; 
Gaspar, P.; et al. Seroprevalence of 
anti-SARS-CoV-2 antibodies in COVID-
19 patients and healthy volunteers 
up to 6 months post disease onset. 
Eur. J. Immunol. 2020, 50, 2025-2040, 
doi:10.1002/eji.202048970.
[22] CDC Vaccines: The Basics 2012.
[23] Anderson, E.J.; Rouphael, N.G.; 
Widge, A.T.; Jackson, L.A.; Roberts, 
P.C.; Makhene, M.; Chappell, J.D.; 
Denison, M.R.; Stevens, L.J.; Pruijssers, 
A.J.; et al. Safety and Immunogenicity 
of SARS-CoV-2 mRNA-1273 Vaccine 
in Older Adults. N. Engl. J. Med. 
2020, 383, 2427-2438, doi:10.1056/
NEJMoa2028436.
[24] Folegatti, P.M.; Ewer, K.J.; Aley, 
P.K.; Angus, B.; Becker, S.; Belij-
Rammerstorfer, S.; Bellamy, D.; Bibi, 
S.; Bittaye, M.; Clutterbuck, E.A.; 
et al. Safety and immunogenicity 
of the ChAdOx1 nCoV-19 vaccine 
against SARS-CoV-2: a preliminary 
report of a phase 1/2, single-blind, 
randomised controlled trial. Lancet 
2020, 396, 467-478, doi:10.1016/
S0140-6736(20)31604-4.
[25] Xia, S.; Zhang, Y.; Wang, Y.; Wang, 
H.; Yang, Y.; Gao, G.F.; Tan, W.; Wu, 
G.; Xu, M.; Lou, Z.; et al. Safety and 
immunogenicity of an inactivated 
SARS-CoV-2 vaccine, BBIBP-CorV: a 
Biotechnology to Combat COVID-19
16
randomised, double-blind, placebo-
controlled, phase 1/2 trial. Lancet 
Infect. Dis. 2021, 21, 39-51, doi:10.1016/
S1473-3099(20)30831-8.
[26] Russell, S.M.; Alba-Patiño, A.; 
Barón, E.; Borges, M.; Gonzalez-
Freire, M.; De La Rica, R. Biosensors 
for Managing the COVID-19 Cytokine 
Storm: Challenges Ahead. ACS Sensors 
2020, 5, 1506-1513, doi:10.1021/
acssensors.0c00979.
[27] Fukumoto, T.; Iwasaki, S.; Fujisawa, 
S.; Hayasaka, K.; Sato, K.; Oguri, S.; 
Taki, K.; Nakakubo, S.; Kamada, K.; 
Yamashita, Y.; et al. Efficacy of a novel 
SARS-CoV-2 detection kit without 
RNA extraction and purification. 
Int. J. Infect. Dis. 2020, 98, 16-17, 
doi:10.1016/j.ijid.2020.06.074.
[28] Laghrib, F.; Saqrane, S.; El Bouabi, 
Y.; Farahi, A.; Bakasse, M.; Lahrich, S.; 
El Mhammedi, M.A. Current progress 
on COVID-19 related to biosensing 
technologies: New opportunity for 
detection and monitoring of viruses. 
Microchem. J. 2021, 160, 105606.
[29] Xi, H.; Juhas, M.; Zhang, Y. 
G-quadruplex based biosensor: 
A potential tool for SARS-CoV-2 
detection. Biosens. Bioelectron. 
2020, 167, 112494, doi:10.1016/j.
bios.2020.112494.
[30] Wong, H.Y.F.; Lam, H.Y.S.; Fong, 
A.H.T.; Leung, S.T.; Chin, T.W.Y.; Lo, 
C.S.Y.; Lui, M.M.S.; Lee, J.C.Y.; Chiu, 
K.W.H.; Chung, T.W.H.; et al. Frequency 
and Distribution of Chest Radiographic 
Findings in Patients Positive for COVID-
19. Radiology 2020, 296, E72–E78, 
doi:10.1148/radiol.2020201160.
[31] Udugama, B.; Kadhiresan, P.; 
Kozlowski, H.N.; Malekjahani, A.; 
Osborne, M.; Li, V.Y.C.; Chen, H.; 
Mubareka, S.; Gubbay, J.B.; Chan, 
W.C.W. Diagnosing COVID-19: The 
Disease and Tools for Detection. ACS 
Nano 2020, 14, 3822-3835, doi:10.1021/
acsnano.0c02624.
[32] Leblanc, J.J.; Gubbay, J.B.; Li, Y.; 
Needle, R.; Arneson, S.R.; Marcino, 
D.; Charest, H.; Desnoyers, G.; Dust, 
K.; Fattouh, R.; et al. Since January 
2020 Elsevier has created a COVID-19 
resource centre with free information 
in English and Mandarin on the novel 
coronavirus COVID-19. The COVID-19 
resource centre is hosted on Elsevier 
Connect, the company’ s public news 
and information. 2020.
[33] Corman, V.M.; Landt, O.; Kaiser, 
M.; Molenkamp, R.; Meijer, A.; 
Chu, D.K.; Bleicker, T.; Brünink, S.; 
Schneider, J.; Luisa Schmidt, M.; et al. 
Detection of 2019-nCoV by RT-PCR. 
Euro Surveill 2020, 25, 1-8.
[34] Lv, Y.; Wu, R.; Feng, K.; Li, J.; 
Mao, Q.; Yuan, H.; Shen, H.; Chai, X.; 
Li, L.S. Highly sensitive and accurate 
detection of C-reactive protein 
by CdSe/ZnS quantum dot-based 
fluorescence-linked immunosorbent 
assay. J. Nanobiotechnology 2017, 15, 
35, doi:10.1186/s12951-017-0267-4.
[35] Rai, P.; Kumar, B.K.;  
Deekshit, V.K.; Karunasagar, I.; 
Karunasagar, I. Detection technologies 
and recent developments in the 
diagnosis of COVID-19 infection.  
Appl. Microbiol. Biotechnol. 
2021, 105, 441-455, doi:10.1007/
s00253-020-11061-5.
[36] Zhang, Y.; Odiwuor, N.; Xiong, 
J.; Sun, L.; Nyaruaba, R.O.; Wei, 
H.; Tanner, N.A. Rapid molecular 
detection of SARS-CoV-2 (COVID-19) 
virus RNA using colorimetric LAMP. 
medRxiv 2020, 2, doi:10.1101/2020.02.2
6.20028373.
[37] Broughton, J.P.; Deng, X.;  
Yu, G.; Fasching, C.L.; Servellita, V.; 
Singh, J.; Miao, X.; Streithorst, J.A.; 
Granados, A.; Sotomayor-Gonzalez, A.; 
et al. CRISPR–Cas12-based detection 
of SARS-CoV-2. Nat. Biotechnol. 
2020, 38, 870-874, doi:10.1038/
s41587-020-0513-4.
17
Sensor Surface Design with NanoMaterials: A New Platform in the Diagnosis of COVID-19
DOI: http://dx.doi.org/10.5772/intechopen.97056
[38] Lau, Y.L.; Ismail, I. binti; Mustapa, 
N.I. binti; Lai, M.Y.; Soh, T.S.T.; 
Hassan, A.H.; Peariasamy, K.M.; 
Lee, Y.L.; Kahar, M.K.B.A.; Chong, 
J.; et al. Development of a reverse 
transcription recombinase polymerase 
amplification assay for rapid and 
direct visual detection of Severe Acute 
Respiratory Syndrome Coronavirus 2 
(SARS-CoV-2). PLoS One 2021, 16, 2-9, 
doi:10.1371/journal.pone.0245164.
[39] Lassaunière, R.; Frische, A.; Harboe, 
Z.B.; Nielsen, A.C.Y.; Fomsgaard, 
A.; Krogfelt, K.A.; Jørgensen, C.S. 
Evaluation of nine commercial SARS-
CoV-2 immunoassays. medRxiv 2020, 
1-15, doi:10.1101/2020.04.09.20056325.
[40] Mertens, P.; De Vos, N.; 
Martiny, D.; Jassoy, C.; Mirazimi, 
A.; Cuypers, L.; Van den Wijngaert, 
S.; Monteil, V.; Melin, P.; Stoffels, 
K.; et al. Development and Potential 
Usefulness of the COVID-19 Ag 
Respi-Strip Diagnostic Assay in a 
Pandemic Context. Front. Med. 2020, 7, 
doi:10.3389/fmed.2020.00225.
[41] Cai, X.F.; Chen, J.; Hu, J. li; Long, 
Q.X.; Deng, H.J.; Liu, P.; Fan, K.; Liao, 
P.; Liu, B.Z.; Wu, G.C.; et al. A peptide-
based magnetic chemiluminescence 
enzyme immunoassay for serological 
diagnosis of coronavirus disease 2019. 
J. Infect. Dis. 2020, 222, 189-195, 
doi:10.1093/infdis/jiaa243.
[42] Giri, B.; Pandey, S.;  
Shrestha, R.; Pokharel, K.; Ligler, 
F.S.; Neupane, B.B. Review of 
analytical performance of COVID-19 
detection methods. Anal. Bioanal. 
Chem. 2021, 413, 35-48, doi:10.1007/
s00216-020-02889-x.
[43] Infantino, M.; Grossi, V.; Lari, 
B.; Bambi, R.; Perri, A.; Manneschi, 
M.; Terenzi, G.; Liotti, I.; Ciotta, G.; 
Taddei, C.; et al. Diagnostic accuracy 
of an automated chemiluminescent 
immunoassay for anti-SARS-CoV-2 
IgM and IgG antibodies: an Italian 
experience. J. Med. Virol. 2020, 92, 
1671-1675, doi:10.1002/jmv.25932.
[44] Turner, A.P.F. Biosensors: 
Fundamentals and applications - 
Historic book now open access. Biosens. 
Bioelectron. 2015, 65, A1.
[45] Ermolaeva, T.; Farafonova, O.; 
Karaseva, N. Possibilities and Prospects 
of Immunosensors for a Highly Sensitive 
Pesticide Detection in Vegetables and 
Fruits: a Review. Food Anal. Methods 
2019, 12, 2785-2801.
[46] Ramírez, N.B.; Salgado, A.M.; 
Valdman, B. The evolution and 
developments of immunosensors 
for health and environmental 
monitoring: Problems and 
perspectives. Brazilian J. Chem. 
Eng. 2009, 26, 227-249, doi:10.1590/
s0104-66322009000200001.
[47] Goumi, Y. El Electrochemical 
Genosensors: Definition and Fields 
of Application. Int. J. Biosens. 
Bioelectron. 2017, 3, doi:10.15406/
ijbsbe.2017.03.00080.
[48] Silva, A.C.A.; Silva, M.J.B.; Da 
Luz, F.A.C.; Silva, D.P.; De Deus, 
S.L.V.; Dantas, N.O. Controlling the 
cytotoxicity of CdSe magic-sized 
quantum dots as a function of surface 
defect density. Nano Lett. 2014, 14, 
5452-5457, doi:10.1021/nl5028028.
[49] Silva, A.C.A.; Da Silva, S.W.; 
Morais, P.C.; Dantas, N.O. Shell 
thickness modulation in ultrasmall 
CdSe/CdSxSe 1-x/CdS core/shell 
quantum dots via 1-thioglycerol. ACS 
Nano 2014, 8, 1913-1922, doi:10.1021/
nn406478f.
[50] Morais, P. V.; Gomes, V.F.; Silva, 
A.C.A.; Dantas, N.O.; Schöning, 
M.J.; Siqueira, J.R. Nanofilm of ZnO 
nanocrystals/carbon nanotubes as 
biocompatible layer for enzymatic 
biosensors in capacitive field-
effect devices. J. Mater. Sci. 2017, 




[51] Almeida Silva, A.C.; Gratens, X.; 
Chitta, V.A.; Franco, S.D.; Souza Da 
Silva, R.; Condeles, J.F.; Dantas, N.O. 
Effects of ultrasonic agitation on  
the structural and magnetic properties 
of CoFe2O4nanocrystals. Eur. J.  
Inorg. Chem. 2014, doi:10.1002/
ejic.201402563.
[52] Silva, A.C.A.; Freschi, A.P.P.; 
Rodrigues, C.M.; Matias, B.F.; Maia, 
L.P.; Goulart, L.R.; Dantas, N.O. 
Biological analysis and imaging 
applications of CdSe/CdSxSe1−x/CdS 
core–shell magic-sized quantum dot. 
Nanomedicine Nanotechnology, Biol. 
Med. 2016, 12, 1421-1430, doi:10.1016/j.
nano.2016.01.001.
[53] Silva, A.C.A.; Azevedo, F.V.P.V.; 
Zóia, M.A.P.; Rodrigues, J.P.; Dantas, 
N.O.; Melo, V.R.Á.; Goulart, L.R. Magic 
Sized Quantum Dots as a Theranostic 
Tool for Breast Cancer. In Recent Studies 
& Advances in Breast Cancer; Open 
Access eBooks: Wilmington, 2017; pp. 
1-10 ISBN 978-81-935757-2-7.
[54] Souza, G.L. de; Moura, C.C.G.; 
Silva, A.C.A.; Marinho, J.Z.; Silva, T.R.; 
Dantas, N.O.; Bonvicini, J.F.S.; Turrioni, 
A.P. Effects of zinc oxide and  
calcium–doped zinc oxide nanocrystals 
on cytotoxicity and reactive oxygen 
species production in different 
cell culture models. Restor. Dent. 
Endod. 2020, 45, 54, doi:10.5395/
rde.2020.45.e54.
[55] Duarte, C.A.; Goulart, L.R.; 
Filice, L. de S.C.; Lima, I.L. de; 
Campos-Fernández, E.; Dantas, N.O.; 
Silva, A.C.A.; Soares, M.B.P.; Santos, 
R.R. dos; Cardoso, C.M.A.; et al. 
Characterization of Crystalline Phase 
of TiO2 Nanocrystals, Cytotoxicity and 
Cell Internalization Analysis on Human 
Adipose Tissue-Derived Mesenchymal 
Stem Cells. Materials (Basel). 2020, 13, 
4071, doi:10.3390/ma13184071.
[56] Carvalho Naves, M.P.; de 
Morais, C.R.; Silva, A.C.A.; Dantas, 
N.O.; Spanó, M.A.; de Rezende, 
A.A.A. Assessment of mutagenic, 
recombinogenic and carcinogenic 
potential of titanium dioxide 
nanocristals in somatic cells of 
Drosophila melanogaster. Food 
Chem. Toxicol. 2018, 112, 273-228, 
doi:10.1016/j.fct.2017.12.040.
[57] Reis, É. de M.; de Rezende, 
A.A.A.; Santos, D.V.; de Oliveria, P.F.; 
Nicolella, H.D.; Tavares, D.C.; Silva, 
A.C.A.; Dantas, N.O.; Spanó, M.A. 
Assessment of the genotoxic potential 
of two zinc oxide sources (amorphous 
and nanoparticles) using the in vitro 
micronucleus test and the in vivo wing 
somatic mutation and recombination 
test. Food Chem. Toxicol. 2015, 84, 55-63, 
doi:10.1016/j.fct.2015.07.008.
[58] Reis, É. de M.; Rezende, A.A.A. 
de; Oliveira, P.F. de; Nicolella, H.D.; 
Tavares, D.C.; Silva, A.C.A.; Dantas, 
N.O.; Spanó, M.A. Evaluation of 
titanium dioxide nanocrystal-induced 
genotoxicity by the cytokinesis-block 
micronucleus assay and the Drosophila 
wing spot test. Food Chem. Toxicol. 
2016, 96, 309-319, doi:10.1016/j.
fct.2016.08.023.
[59] Silva, A.; Zóia, M.A.P.; Correia, 
L.I.V.; Azevedo, F.V.P.V.; Paula, A.T. 
de; Maia, L.P.; Carvalho, L.S. de; 
Carvalho, L.N.; Costa, M.P.C.; Giaretta, 
L.C.; et al. Biocompatibility of Doped 
Semiconductors Nanocrystals and 
Nanocomposites. In Cytotoxicity; 
InTech, 2018.
[60] Silva, A.C.A.; Dantas, N.O.; Silva, 
M.J.B.; Spanó, A.M.; Goulart, ; Luiz 
Ricardo Functional Nanocrystals : 
Towards Biocompatibility, Nontoxicity 
and. In Advances in Biochemistry & 
Applications in Medicine; 2017; pp. 1-27.
[61] Souza, G.L.; Silva, T.R.; Vieira, 
M.S.; Dantas, N.O.; Silva, A.C.A.; 
Moura, C.C.G. Development and 
19
Sensor Surface Design with NanoMaterials: A New Platform in the Diagnosis of COVID-19
DOI: http://dx.doi.org/10.5772/intechopen.97056
study of cytotoxicity of calcium oxide 
nanocrystals - ScienceDirect. Dent. 
Mater. 2018, 34, e83.
[62] Silva, A.C.A.; Correia, L.I.V.; Silva, 
M.J.B.; Zóia, M.A.P.; Azevedo, F.V.P.V.; 
Rodrigues, Jéssica Peixoto Goulart, 
L.R.; Ávila, Veridiana de Melo Dantas, 
N.O. Biocompatible Magic Sized 
Quantum Dots: Luminescent Markers 
and Probes. In; Correia, L.I.V., Ed.; 
IntechOpen: Rijeka, 2018; p. Ch. 6 ISBN 
978-1-78923-295-0.
[63] Silva, A.C.A.; Deus, S.L.V. De; 
Silva, M.J.B.; Dantas, N.O. Highly stable 
luminescence of CdSe magic-sized 
quantum dots in HeLa cells. Sensors 
Actuators, B Chem. 2014, 191, 108-114, 
doi:10.1016/j.snb.2013.09.063.
[64] Pilla, V.; De Lima, S.R.; Andrade, 
A.A.; Silva, A.C.A.; Dantas, N.O. 
Fluorescence quantum efficiency 
of CdSe/CdS magic-sized quantum 
dots functionalized with carboxyl or 
hydroxyl groups. Chem. Phys. Lett. 
2013, 580, 130-134, doi:10.1016/j.
cplett.2013.07.007.
[65] Almeida Silva, A.; Freitas Neto, 
E.; da Silva, S.W.; Morais, P.; Dantas, 
N. Modified Phonon Confinement 
Model and Its Application to CdSe/CdS 
Core–Shell Magic-Sized Quantum Dots 
Synthesized in Aqueous Solution by a 
New Route. J. Phys. Chem. C 117, 1904-
1914, doi:10.1021/jp308500r.
[66] Almeida Silva, A.; Silva, M.J.; da 
Luz, F.A.; Silva, D.; de Deus, S.; Dantas, 
N. Controlling the Cytotoxicity of 
CdSe Magic-Sized Quantum Dots as 
a Function of Surface Defect Density. 
Nano Lett. 14, 5452-5457, doi:10.1021/
nl5028028.
[67] Silva, A.C. a; da Silva, S.W.; Morais, 
P.C.; Dantas, N.O. Shell Thickness 
Modulation in Ultrasmall CdSe/
CdSxSe1-x/CdS Core/Shell Quantum 
Dots via 1-Thioglycerol. ACS Nano 2014, 
8, 1913-1922, doi:10.1021/nn406478f.
[68] Dias, E.H.V.; Pereira, D.F.C.; 
de Sousa, B.B.; Matias, M.S.; de 
Queiroz, M.R.; Santiago, F.M.; Silva, 
A.C.A.; Dantas, N.O.; Santos-Filho, 
N.A.; de Oliveira, F. In vitro tracking 
of phospholipase A 2 from snake 
venom conjugated with magic-sized 
quantum dots. Int. J. Biol. Macromol. 
2019, 122, 461-468, doi:10.1016/j.
ijbiomac.2018.10.185.
[69] Sandino, J.; Pegg, G.; Gonzalez, F.; 
Smith, G. Aerial Mapping of Forests 
Affected by Pathogens Using UAVs, 
Hyperspectral Sensors, and Artificial 
Intelligence. Sensors 2018, 18, 944, 
doi:10.3390/s18040944.
[70] Naudé, W. Artificial Intelligence 
Against Covid-19: An Early Review. IZA 
Discuss. Pap. No. 13110 2020, 1-17.
[71] Silva, A.C.A.; Dantas, N.O.; Silva, 
M.J.B.; Spanó, M.A.; Goulart, L.R. 
Functional Nanocrystals : Towards 
Biocompatibility, Nontoxicity 
and Biospecificity. In Advances in 
Biochemistry & Applications in Medicine; 
Rojeet Shrestha, Ed.; Open Access 
eBooks: Wilmington, 2017; pp. 1-27 
ISBN 978-81-935757-1-0.
[72] de Lima França, C.C.; da Silva 
Terto, E.G.; Dias-Vermelho, M. V.; 
Silva, A.C.A.; Dantas, N.O.; de Abreu, 
F.C. The electrochemical behavior 
of core-shell CdSe/CdS magic-sized 
quantum dots linked to cyclodextrin for 
studies of the encapsulation of bioactive 
compounds. J. Solid State Electrochem. 
2016, 20, 2533-2540, doi:10.1007/
s10008-016-3221-8.
[73] Vadlamani, B.S.; Uppal, T.; Verma, 
S.C.; Misra, M. Functionalized TiO2 
Nanotube-Based Electrochemical 
Biosensor for Rapid Detection of 
SARS-CoV-2. Sensors 2020, 20, 5871, 
doi:10.3390/s20205871.
[74] Cui, F.; Zhou, H.S. Diagnostic 
methods and potential portable 
biosensors for coronavirus disease 2019. 
Biotechnology to Combat COVID-19
20
Biosens. Bioelectron. 2020, 165, 112349, 
doi:10.1016/j.bios.2020.112349.
[75] Mahshid, S.S.; Flynn, S.E.; 
Mahshid, S. The potential application 
of electrochemical biosensors in the 
COVID-19 pandemic: A perspective on 
the rapid diagnostics of SARS-CoV-2. 
Biosens. Bioelectron. 2021, 176, 112905, 
doi:10.1016/j.bios.2020.112905.
[76] Seo, G.; Lee, G.; Kim, M.J.; Baek, 
S.H.; Choi, M.; Ku, K.B.; Lee, C.S.; Jun, 
S.; Park, D.; Kim, H.G.; et al. Rapid 
Detection of COVID-19 Causative 
Virus (SARS-CoV-2) in Human 
Nasopharyngeal Swab Specimens Using 
Field-Effect Transistor-Based Biosensor. 
ACS Nano 2020, 14, 5135-5142, 
doi:10.1021/acsnano.0c02823.
[77] Rashed, M.Z.; Kopechek, J.A.; 
Priddy, M.C.; Hamorsky, K.T.; Palmer, 
K.E.; Mittal, N.; Valdez, J.; Flynn, J.; 
Williams, S.J. Rapid detection of SARS-
CoV-2 antibodies using electrochemical 
impedance-based detector. Biosens. 
Bioelectron. 2021, 171, 112709, 
doi:10.1016/j.bios.2020.112709.
[78] Mojsoska, B.; Larsen, S.; Olsen, 
D.A.; Madsen, J.S.; Brandslund, I.; 
Alatraktchi, F.A. Rapid SARS-CoV-2 
detection using electrochemical 
immunosensor. Sensors (Switzerland) 
2021, 21, 1-11, doi:10.3390/s21020390.
[79] Yakoh, A.; Pimpitak, U.; Rengpipat, 
S.; Hirankarn, N.; Chailapakul, O.; 
Chaiyo, S. Paper-based electrochemical 
biosensor for diagnosing COVID-19: 
Detection of SARS-CoV-2 antibodies 
and antigen. Biosens. Bioelectron. 
2021, 176, 112912, doi:10.1016/j.
bios.2020.112912.
[80] Zhao, H.; Liu, F.; Xie, W.; Zhou, 
T.C.; OuYang, J.; Jin, L.; Li, H.; 
Zhao, C.Y.; Zhang, L.; Wei, J.; et al. 
Ultrasensitive supersandwich-type 
electrochemical sensor for SARS-CoV-2 
from the infected COVID-19 patients 
using a smartphone. Sensors Actuators, 
B Chem. 2021, 327, doi:10.1016/j.
snb.2020.128899.
[81] Eissa, S.; Zourob, M. Development 
of a Low-Cost Cotton-Tipped 
Electrochemical Immunosensor 
for the Detection of SARS-CoV-2. 
Anal. Chem. 2021, doi:10.1021/acs.
analchem.0c04719.
[82] Fabiani, L.; Saroglia, M.; Galatà, 
G.; De Santis, R.; Fillo, S.; Luca, V.; 
Faggioni, G.; D’Amore, N.; Regalbuto, 
E.; Salvatori, P.; et al. Magnetic beads 
combined with carbon black-based 
screen-printed electrodes for COVID-
19: A reliable and miniaturized 
electrochemical immunosensor for 
SARS-CoV-2 detection in saliva. 
Biosens. Bioelectron. 2021, 171, 112686, 
doi:10.1016/j.bios.2020.112686.
[83] Hashemi, S.A.; Golab Behbahan, 
N.G.; Bahrani, S.; Mousavi, S.M.; 
Gholami, A.; Ramakrishna, S.; 
Firoozsani, M.; Moghadami, M.; 
Lankarani, K.B.; Omidifar, N. Ultra-
sensitive viral glycoprotein detection 
NanoSystem toward accurate tracing 
SARS-CoV-2 in biological/non-
biological media. Biosens. Bioelectron. 
2021, 171, 112731, doi:10.1016/j.
bios.2020.112731.
[84] Li, X.; Qin, Z.; Fu, H.; Li, T.; 
Peng, R.; Li, Z.; Rini, J.M.; Liu, X. 
Enhancing the performance of paper-
based electrochemical impedance 
spectroscopy nanobiosensors: An 
experimental approach. Biosens. 
Bioelectron. 2021, 177, 112672, 
doi:10.1016/j.bios.2020.112672.
[85] Alafeef, M.; Dighe, K.; Moitra, 
P.; Pan, D. Rapid, Ultrasensitive, and 
Quantitative Detection of SARS-CoV-2 
Using Antisense Oligonucleotides 
Directed Electrochemical Biosensor 
Chip. ACS Nano 2020, 14, 17028-17045, 
doi:10.1021/acsnano.0c06392.
[86] Torrente-Rodríguez, R.M.; Lukas, 
H.; Tu, J.; Min, J.; Yang, Y.; Xu, C.; 
21
Sensor Surface Design with NanoMaterials: A New Platform in the Diagnosis of COVID-19
DOI: http://dx.doi.org/10.5772/intechopen.97056
Rossiter, H.B.; Gao, W. SARS-CoV-2 
RapidPlex: A Graphene-Based 
Multiplexed Telemedicine Platform 
for Rapid and Low-Cost COVID-19 
Diagnosis and Monitoring. Matter 
2020, 3, 1981-1998, doi:10.1016/j.
matt.2020.09.027.
